|
|
 |
|
Viewing report
|
|
|
|
OTC Obesity in Greece
Euromonitor International, March 2010, Pages: 33
In line with EU regulations, products in OTC obesity were not available in Greece in 2008. However, in October 2008, the European Medicines Agency (EMEA) authorised the switching of active ingredient Orlistat (60mg). In this context, GlaxoSmithKline was granted licence for the launch of its Alli brand in Greece, introduced at the end of November 2009. Available in a bottle of 84 hard capsules of 60mg, this “diet pill” is characterised as GlaxoSmithKline’s “de-tuned” version of the popular...
The OTC Obesity Products in Greece report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.
Product coverage:
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the Consumer Health industry;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
.
Customers who bought this item also bought
Wound Treatments in Greece
Slimming Products in Greece
Emergency Contraception in Greece
Cough, Cold and Allergy (Hay Fever) Remedies in Greece
OTC Obesity in Austria
OTC Obesity in Poland
OTC Obesity in Portugal
Digestive Remedies in Greece
OTC Obesity in Spain
OTC Obesity in France
|
|
|
|
